Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244881 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00244881: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00244881 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00244881, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
AZD2171 (cediranib maleate) may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying how well AZD2171 works in treating patients with refractory stage IV breast cancer
Interventions
- OTHER laboratory biomarker analysis
- DRUG cediranib maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244881
The ClinicalTrials.gov registry entry for NCT00244881 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00244881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244881 about?
NCT00244881 is a clinical study titled "A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)". AZD2171 (cediranib maleate) may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying how well AZD2171 works in treating patients with refractory stage IV breast cancer
What is the current status of trial NCT00244881?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2005-09. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00244881?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cediranib maleate (DRUG).
Who is sponsoring clinical trial NCT00244881?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.